Ann Marie Trentacosti, CDER Office of New Drugs (OND), discusses considerations for labeling content in the prescribing information that may not be specifically addressed in currently published FDA guidances.
-------------------------

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: [ Ссылка ]

CDER SBIA 2017 Playlist: [ Ссылка ]
LinkedIn: [ Ссылка ]
Training resources: [ Ссылка ]

Twitter: [ Ссылка ]

CDER small business e-mail update subscription: [ Ссылка ]

Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367

свернуть